Knowledge Center

11 November 2026
Oncology Clinical Trials in South Korea: ADC Landscape
Oncology clinical trials in South Korea: in-label IITs can target first patient in roughly 3-4 months and build early ADC evidence for global program planning.

27 October 2026
Personalized Cancer Vaccines: Lessons from INTerpath-001
INTerpath-001 is the first positive Phase 3 trial of a personalized cancer vaccine. What it means for trial design, immune monitoring and supply chains.

16 October 2026
Why CNS Clinical Trials Fail and How to Adapt
Screen failure, attrition, and heterogeneity in CNS clinical trials often trace back to how the trial is designed, not the underlying biology. Here's what to fix, and when.

9 October 2026
7 Alzheimer’s Biomarkers That Inform Trial Design
Deferring biomarker confirmation risks the wrong population or misaligned endpoints. Learn which Alzheimer's biomarkers matter and why to plan early.

9 October 2026
7 Decisions That Shape Your Path from Preclinical to Clinical
Your clinical hold rate can hinge on decisions made months before the regulatory submission. Learn 7 preclinical decisions that shape a smooth path to clinical.

4 September 2026
First-in-Human vs. First-in-Patient: How to Choose
The first-in-human vs. first-in-patient decision affects your timeline, data, and your next investor conversation. A drug development expert outlines the study choices.

21 August 2026
Enhance Your Recruitment & Retention Strategy For Rare Kidney Disease Trials
Breakthroughs in genetic understanding alongside the growing shift toward accommodating orphan drugs have led to an upswing in clinical trials for rare kidney disease.

6 August 2026
The Rise of Chinese Biotechs and the Global CRO Question
What's fueling the surge of Chinese biotechs onto the world stage, and what decisions do they face on the path to their first global clinical trial?

27 May 2026
How Australia’s Leading CRO Is Driving Biotech’s Acceleration From First-In-Human To Global Markets
In 2025, Harvill’s experience overseeing CROs through global expansion across Asia Pacific (APAC), Europe, and South America led him to take the helm at Avance Clinical, Australia’s leading CRO.

11 March 2026
CNS Trials Are Difficult — Do They Have To Be?
Central nervous system (CNS) indications, including mood disorders, neurodegenerative and neurodevelopmental diseases, and chronic pain, affect more than three billion people worldwide and represent the leading cause of illness and disability globally1.

11 February 2026
Why Early CRO Choice Is Critical To Accelerating Delivery Of Your Clinical Program
Australia's pragmatic regulatory environment, accelerated timelines, globally accepted data, Research and Development Tax Incentive, and other advantages, have emerged as a compelling strategy for Phase I trials.

20 November 2025
International Clinical Trials Autumn Issue Is Live
The latest International Clinical Trials (ICT) Autumn Issue is now live, featuring an exclusive interview with Jemma Lawson, Avance Clinical’s Executive Vice President, Global Operations.
Proven industry
experience & expertise
800+
Studies in the past 10 years
500+
Experienced team members
33k+
Participants past 10 years
30
Years of CRO experience